Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the world and is characterized by impaired pulmonary function and progressive airway obstruction. 1, 2 It is estimated that 10% of persons older than 40 years have COPD. 3 Impaired pulmonary function and airway obstruction are commonly diagnosed based on spirometric measurements of FEV 1 and its ratio to forced vital capacity (FVC). 4 Common genetic variants underlying pulmonary function have been identified by several genome-wide association studies (GWAS). Multiple single nucleotide polymorphisms (SNPs) From were found to be associated with FEV 1 , FEV 1 /FVC or both in population-based studies, including both ever-smokers and never-smokers, among other SNPs annotated to the genes ADAM13, AGAR, CHRNA3/5, FAM13A, GPR126, HHIP, HTR4, PID1, PTCH1, and THSD4. [5] [6] [7] Several of these genes (ie, CHRNA3/5, FAM13A, and HHIP) were also identified in case-control studies investigating the risk for COPD, including only ever-smokers with at least 2.5 pack-years of smoking. 8, 9 Cigarette smoking is considered the most important risk factor for airway obstruction in the industrialized world. 2 This explains the predominantly smoking-related focus of previous studies on COPD susceptibility genes yet ignores the potential genetics underlying COPD development in never-smokers. Our previous candidate gene-based research suggested that some genes are related to pulmonary function impairment or COPD in both ever-smokers and never-smokers [10] [11] [12] ; however, other genes seem to affect pulmonary function exclusively in never-smokes. 13 Thus far, little research has focused explicitly on assessing the genetic background of airway obstruction in never-smokers, although a striking proportion of 25% to 45% of patients with COPD worldwide are never-smokers. 14 Few GWAS on continuous FEV 1 and FEV 1 /FVC levels have presented stratified results by smoking status and then only for their top hits selected based on analyses including both ever-smokers and never-smokers. 6, 7, 15 Thus far, 2 studies have performed genome-wide association analyses separately in ever-smokers and never-smokers and investigated pulmonary function as a dichotomous outcome (airway obstruction or extremes of FEV 1 , respectively) rather than a continuous outcome. 5, 16 The current study aimed to identify common genetic variants associated with pulmonary function (FEV 1 and FEV 1 /FVC as continuous outcomes) in never-smokers and aimed to assess the effects of these variants in more detail by performing genetic risk score (GRS) and expression quantitative trait locus (eQTL) analyses. Additionally, we also investigated the genetic effects in ever-smokers and SNP*ever-smoking interactions.
METHODS

Subject selection
All never-smokers with available genotype data from the Dutch populationbased cohort study LifeLines were included as the identification cohort. 17 To verify our findings, we analyzed never-smokers of 4 independent verification cohorts, namely the Vlagtwedde-Vlaardingen study 18 and the 3 cohorts of the Rotterdam Study (I-III). 19, 20 Subjects were defined as never-smokers based on self-reported never-smoking history with 0 pack-years of smoking. All subjects provided written informed consent, and the studies were approved by the medical ethics committee of either the University Medical Center Groningen (LifeLines and Vlagtwedde-Vlaardingen cohorts) or the Erasmus University (Rotterdam Study I-III). Additional details on the cohorts are provided in the Methods section in this article's Online Repository at www.jacionline.org.
Genotyping
In the LifeLines cohort study and the Vlagtwedde-Vlaardingen study Illumina CytoSNP-12 arrays (Illumina, San Diego, Calif) were used to genotype blood samples. 17, 18 Illumina Human610-Quad BeadChips were used to genotype blood samples of the Rotterdam Study (I-III). 19 SNPs with a genotype call rate of 95% or greater, a minor allele frequency of 1% or greater, and a Hardy-Weinberg P value of 10 24 or greater were included. Samples from nonwhite subjects and first-degree relatives were excluded based on self-reporting, outlier (identity-by-state), and principal components analysis.
Statistical analysis
After quality control, a total of 227,981 genotyped SNPs were included in the identification analysis. Genome-wide association analyses were performed on 2 spirometric measures of pulmonary function (ie, prebronchodilator FEV 1 21 PLINK 22 and GRIMP 23 software packages were used for the genome-side association analyses. Linear regression models (additive genetic model) were adjusted for sex, age, and height. The major allele was used as the reference allele, and the reported effect estimates are for the minor allele (A1). Genotyped SNPs associated with pulmonary function with a P value of less than 10 25 in the identification analysis were selected for verification. Analyses were performed in the 4 verification cohorts separately and then meta-analyzed by using effect estimates weighted by the inverse of the SEs with METAL. 24 Genotyped SNPs with a meta-analyzed fixed-effects P value of less than .05 and with the same direction of effect in all cohorts were considered to be significantly replicated.
GRS analysis
A GRS was constructed for each subject by calculating the total number of risk alleles of the replicated SNPs for both the identification and replication cohorts separately to assess the cumulative effect of the replicated SNPs on pulmonary function. Using SPSS software (SPSS, Chicago, Ill), 25 linear regression models were adjusted for sex, age, and height. Subsequently, we meta-analyzed the effect estimates of the 4 verification cohorts and all 5 cohorts.
Gene expression analysis (eQTL analysis)
We assessed whether the selected SNPs were cis-acting eQTLs using a lung tissue database established by the lung eQTL consortium. 26 In total, 1087 subjects were included, and probe sets located within 2 Mb of the replicated SNPs (4 Mb window) were selected. The linear regression model was adjusted for disease status, age, sex, smoking status, and cohort-specific principal components. SNPs with a P value below the Bonferroni-corrected threshold (P 5 .05/number of probes in window) were considered significantly associated with gene expression level (mRNA). As a sensitivity analysis, we performed the same analysis in only never-smokers of the lung tissue database (n 5 155) for the significant SNP probe set combinations. See the Methods section in this article's Online Repository and Gene Expression Omnibus accession numbers GSE23546 and GPL10379 for additional information.
Ever-smokers
Ever-smokers of the identification cohort LifeLines were investigated to assess whether the replicated SNPs were associated with pulmonary function in smokers as well. Ever smoking was based on self-reported smoking history and having smoked for more than 5 pack-years. Linear regression models were adjusted for sex, age, height, pack-years, and current smoking. In addition, we tested whether the associations of the replicated SNPs with pulmonary function were significantly different between ever-smokers and never-smokers by adding the interaction term SNP*ever-smoking to the model (adjusted for sex, age, height, pack-years, and ever smoking).
RESULTS
Population characteristics
An overview of the study design is shown in Fig E1 in this article's Online Repository at www.jacionline.org. Complete data on all covariates were available for 7036 subjects of the 5 cohorts (identification cohort, n 5 5070; verification cohorts, n 5 1966). The characteristics of never-smokers included in all cohorts are shown in Table I , 27 and those for ever-smokers of the identification cohort LifeLines are shown in Table E1 in this article's Online Repository at www.jacionline.org. Of interest, based on prebronchodilator measurements, the identification cohort included 548 never-smokers (11%) with airway obstruction (FEV 1 /FVC <70%) and 106 never-smokers (2%) with Global Initiative for Chronic Obstructive Lung Disease COPD stage 2 or higher (FEV 1 /FVC <70%; FEV 1 percent predicted <80%). The genomic inflation factor lambda was low (l 5 1.02) for both analyses on FEV 1 and FEV 1 /FVC levels in the identification sample, indicating minimal population stratification. The quantile-quantile plots can be found in Fig  E2 in this article's Online Repository at www.jacionline.org.
FEV 1
Only 1 SNP (rs17057154) was associated with FEV 1 level with a P value of less than 10 25 in never-smokers of the identification cohort (see Fig E3, A, and Table E2 in this article's Online Repository at www.jacionline.org). This SNP was associated with FEV 1 with a P value of less than .05 in the VlagtweddeVlaardingen cohort. The effect estimate was, however, in the opposite direction. Hence this SNP was not further investigated in the Rotterdam Study or in additional analyses.
FEV 1 /FVC
We identified 5 SNPs associated with FEV 1 /FVC level in never-smokers in the identification cohort (P < 10 25 ; Table II  and see Fig E3, B) . The associations of these 5 SNPs with FEV 1 and FVC levels separately can be found in Table E3 in this article's Online Repository at www.jacionline.org. In the verification meta-analysis, 2 of these SNPs were associated with FEV 1 /FVC level (fixed-effect P < .05) and had the same direction of effect in all cohorts (Fig 1, A and B , and see Table  E4 in this article's Online Repository at www.jacionline.org). In addition, when meta-analyzing all 5 cohorts, both identification and verification cohorts, the same 2 SNPs reached genomewide significance according to the Bonferroni-corrected threshold (P < 2.19 3 10
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, Table II ). The replicated SNPs are located in or near the genes hedgehog interacting protein (HHIP; rs1512282) and family with sequence similarity 13, member a (FAM13A; rs6849143). Regional association plots are shown in Fig E4 in (14) 98 (15) 109 (22) 108 (18) 106 (17) FEV 1 /FVC (%), mean (SD) 78 (7) 76 (7) 77 (7) 79 (6) 78 (6) FEV 1 /FVC < 70%, no. (%)
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SNPs were selected in the identification cohort based on a P value of less than 10
25
. Associations between SNPs and FEV 1 /FVC (as percentages) were analyzed by using linear regression adjusted for sex, age, and height. Results of the separate verification studies can be found in Table E4 . SNPs with a P value below the Bonferroni-corrected P value of 2.19 3 10 27 were considered genome-wide significant. 1, Positive effect estimate; 2, negative effect estimate. A1, minor allele (effect allele); B, effect estimate; I 2 , heterogeneity measure; MAF, minor allele frequency. *Verification cohorts: Vlagtwedde-Vlaardingen and Rotterdam Study I to III.
Order: LifeLines, Vlagtwedde-Vlaardingen, and Rotterdam Study I to III. in never-smokers (see Fig E5, A, in this article's Online Repository at www.jacionline.org). SNP rs6849143 is located within an intron of FAM13A (4q22.1), with the minor allele (T; minor allele frequency, 43%) being associated with lower FEV 1 /FVC levels (see Fig E5, B) .
GRS analysis
We performed a GRS analysis using the 2 replicated SNPs to assess their cumulative effect on FEV 1 /FVC levels in neversmokers of the identification and verification cohorts. In the identification cohort the GRS indicated a strong significant association and an additive effect for each additional risk allele (B 5 20.58% FEV 1 /FVC, P 5 2.87 3 10
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, see Fig E6 in this article's Online Repository at www.jacionline.org). FEV 1 / FVC levels in subjects carrying all 4 risk alleles were significantly lower (2.4%) compared with those in subjects not carrying any risk allele (adjusted mean FEV 1 /FVC level of 78.3% and 80.7%, respectively). The GRS was also significant and had a similar effect estimate in the meta-analysis of the verification cohorts (B 5 20.53%) and all cohorts (B 5 20.57%; Fig 1, C) .
Gene expression analysis (eQTL analysis)
We found significant associations of the 2 replicated SNPs with gene expression levels (mRNA level) in lung tissue (Fig 2, Table  III , and see Fig E7 in this article's Online Repository at www. jacionline.org). The minor allele (G) of SNP rs1512282 was significantly associated with decreased levels of expression of 3 probe sets located in HHIP. The minor allele (T) of SNP rs6849143 was significantly associated with increased expression of a probe set in the gene tigger transposable element derived 2 (TIGD2) and with increased expression of 3 probe sets located in FAM13A. When limiting the eQTL analysis to only never-smokers (n 5 155), we find comparable effect estimates for the most significant probe sets in HHIP and FAM13A (Table III) .
Ever-smokers
To assess whether the replicated SNPs were associated with FEV 1 /FVC levels in ever-smokers as well, we investigated associations in ever-smokers (>5 pack-years) of the identification cohort (Table IV) . The minor allele (G) of the SNP near HHIP (rs1512282) was associated with a higher FEV 1 /FVC level in ever-smokers, with an effect estimate almost identical to the association in never-smokers. In line with these observations, the interaction analysis did not show a significant interaction between the SNP and ever smoking. The effect estimate for the FAM13A SNP (rs6849143) was lower in ever-smokers than in never-smokers and not significant (P > .05) in ever-smokers. The interaction analysis showed a borderline significant interaction between the SNP and ever smoking (P 5 .07).
DISCUSSION
The current study assessed the genetic background of pulmonary function as a continuous outcome (FEV 1 and FEV 1 /FVC) in exclusively never-smokers. We identified 2 common genetic variants annotated to the genes HHIP and FAM13A to be associated with FEV 1 /FVC levels in never-smokers. The risk alleles of the SNPs account for lower FEV 1 /FVC level and therefore confer a risk for airway obstruction. Our results imply that the genes HHIP and FAM13A are general susceptibility genes for the development of airway obstruction and confer an effect regardless of exposure to the most important risk factor of COPD: cigarette smoking.
The genes HHIP and FAM13A are well-known genes associated with pulmonary function and COPD and have been previously identified in several GWAS. [5] [6] [7] [8] [9] However, these studies C, GRS, which was created by adding up the number of alleles (risk alleles) for both HHIP and FAM13A SNPs associated with a lower FEV 1 /FVC. A value of 0 means no risk alleles for both SNPs, and a value of 4 means a subject is carrying all 4 risk alleles of both SNPs. B and 95% CI represent the mean difference in percentage FEV 1 /FVC for each additional allele relative to the wild-type (adjusted for sex, age, and height).
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were performed in ex-smokers or current smokers only 8, 9 or in a general population adjusted for smoking. 6, 7 In the current study SNPs annotated to HHIP and FAM13A were associated with continuous FEV 1 /FVC levels in a sample of exclusively never-smokers, and these associations were successfully replicated in a meta-analysis of 4 independent cohorts. Of interest, when meta-analyzing all 5 included cohorts (identification and replication), both HHIP and FAM13A SNPs reached genome-wide significance (Table II) .
As described in the introduction, 2 previous studies have performed genome-side association analyses separately in never-smokers and ever-smokers, yet investigated pulmonary function as a dichotomous outcome. The study by Wilk et al 5 did not identify associations between HHIP or FAM13A and airway obstruction in never-smokers but did so among all participants. Furthermore, no differences in associations were identified between heavy smokers and never-smokers for the HHIP locus when assessing low FEV 1 versus high FEV 1 in the study by Wain et al. 16 Results of the FAM13A locus were not presented because it was not identified as a top hit.
In the current study we found similar effect estimates of FEV 1 / FVC level and the HHIP SNP in ever-smokers and neversmokers. Effect estimates of FEV 1 /FVC level in ever-smokers compared with never-smokers for the FAM13A SNP were lower yet without a significant interaction between ever smoking and this SNP. In line with this finding, we also did not observe a significant SNP*ever-smoking interaction associated with gene expression of HHIP and FAM13A in our eQTL analysis (see Table E5 in this article's Online Repository at www.jacionline. org). Likewise, in the study by Soler Artigas et al, 15 no significant differences in associations between FEV 1 /FVC level and HHIP or FAM13A SNPs were identified between ever-smokers and never-smokers, yet this might have been expected because these SNPs were selected based on a meta-analysis of association in ever-smokers and never-smokers. In conclusion, results of the current study show that the genes HHIP and FAM13A play a role in airway obstruction in never-smokers, thus conferring an effect regardless of exposure to cigarette smoking.
The GRS analysis showed that the combined effect estimate for the 2 independent SNPs annotated to FAM13A and HHIP accounted for a 2.4% lower FEV 1 /FVC level, a credible and clinically relevant effect. These findings are supported by the results of Soler Artigas et al, 28 who also showed a higher risk for COPD with more risk alleles for 5 known COPD genes, including HHIP. Interestingly, a substantial proportion of our study population (ie, 6%) carries all 4 risk alleles. The worldwide prevalences of the risk alleles of the HHIP and FAM13A SNPs are 68% and 47%, respectively. Thus it is likely that similar or even higher percentages of persons worldwide are carrying all 4 risk alleles. Moreover, HHIP and FAM13A have been previously associated with airway obstruction and COPD in Chinese Han, Korean, and Hispanic populations as well. [29] [30] [31] Consequently, HHIP and FAM13A will have an important role in worldwide COPD prevalence.
HHIP and FAM13A might have an independent effect on FEV 1 / FVC level because they are involved in different pathways. HHIP is known to play an important role during lung embryogenesis, involving fetal lung branching development. Hence it is reasonable to assume that the effect of HHIP on pulmonary function can occur independently of smoking history. The identified HHIP SNP in this study is located in an uncharacterized noncoding RNA (http://www.ncbi.nlm.nih.gov/SNP/). Speculatively, this noncoding RNA might be the functional element regulating the HHIP gene through cis-interaction. In the current study the minor allele (G) of the HHIP SNP was associated with lower gene expression of HHIP in lung tissue and a higher FEV 1 /FVC level. Zhou et al 32 showed that HHIP expression, both at the mRNA and protein levels, is lower in lung tissue Linear regression models assessing associations between SNPs and FEV 1 /FVC levels (as percentages) were adjusted for sex, age, and height in the analysis in never-smokers and additionally adjusted for pack-years and current smoking in the analysis in ever-smokers. SNP*ever-smoking interactions were tested in a linear regression model adjusted for sex, age, height, pack-years, and ever smoking.
from patients with COPD compared with that from healthy subjects. They identified a block of genetic variants (679 kb) associated with HHIP expression about 51 kb away from HHIP. However, the genetic variant (rs1512282) identified in the current study is located just outside this region but is in moderate linkage disequilibrium with SNPs located in this block. This area near HHIP might function as an enhancer by interacting with the HHIP promoter through chromatin looping. Decreased HHIP expression, as seen in our lung eQTL analysis, induces an overactivation of the hedgehog pathway. 32 Silencing of HHIP leads to differential expression of about 300 genes enriched for cell growth, lung extracellular matrix, and genes associated with COPD. 33 Together, these findings point toward a plausible role for HHIP as an airway obstruction susceptibility gene, regardless of smoking.
It was suggested that FAM13A might play a role in Rho GTPase signaling based on the presence of a Rho-GAP (Ras homologous GTPase-activation protein) domain in the protein sequence. 34 It was shown that SNPs in linkage disequilibrium with variants in the Rho-GAP domain of FAM13A confer a reduced risk for COPD and lung cancer. 35 Jiang et al 36 showed that FAM13A-null mice were less susceptible to cigarette smoke-induced emphysema and that loss of FAM13A resulted in increased cell proliferation and activation of b-catenin signaling. They suggested that FAM13A can regulate b-catenin degradation, which might contribute to increased emphysema development. They also observed higher FAM13A expression and lower b-catenin protein levels in lung tissue of patients with COPD compared with that seen in healthy ex-smokers. Our eQTL analysis showed that the minor allele of the FAM13A SNP rs6849143 is associated with higher gene expression of TIGD2 and FAM13A in lung tissue. Thus, in line with the literature, our data suggest that genetic variants in FAM13A, through higher expression of FAM13A, increase individual susceptibility to airway obstruction.
Of interest, we did not identify SNPs in the nicotine acetylcholine receptor (CHRNA3/5) locus to be associated with FEV 1 /FVC level in never-smokers. In our study 2 SNPs previously associated with COPD in the CHRNA locus were associated with FEV 1 /FVC level in ever-smokers but not never-smokers, irrespective of the comparable size of both groups (see Table E6 in this article's Online Repository at www.jacionline.org). These finding are in line with results from the only longitudinal study thus far on the CHRNA locus, which showed that SNPs in the CHRNA locus did not have an effect on annual FEV 1 decrease but however associated with smoking habits. 37, 38 Our current findings again suggest that SNPs in the CHRNA locus do not have a direct effect on COPD development but act through nicotine dependence. In addition, we tested other genes previously identified in GWAS on FEV 1 /FVC level in our cohort of never-smokers. The results of this analysis can be found in Table E7 in this article's Online Repository at www.jacionline.org.
Our study has several potential limitations. First, the results of the identification GWAS on FEV 1 were not replicated, and therefore no additional analyses were performed.
Second, because this is an exploratory study, we used a less stringent P value of less than 10 25 for our identification sample. However, we replicated 2 of our findings in a meta-analysis including 4 independent cohorts and reached genome-wide significance according to the Bonferroni-corrected threshold (P < 2.19 3 10 27 ) in a meta-analysis including all 5 cohorts for these same 2 SNPs, with the P value of the HHIP SNP being even lower than 5 3 10 28 (Table II) . This indicates the robustness of our findings.
Third, we did not adjust our analysis for asthma or other risk factors for impaired pulmonary function, such as environmental tobacco smoke and occupational exposures. 2, 14 However, when we adjusted the linear models for asthma, occupational exposures (vapors, gases, dusts and fumes, or pesticides), or environmental tobacco smoke exposure (hours per day or in utero), we found similar effect estimates for the 2 replicated SNPs on FEV 1 /FVC level in never-smokers, suggesting there are no confounding effects in our study (see Table E8 in this article's Online Repository at www.jacionline.org). These findings also indicate that these variants might underlie impaired pulmonary function independently of these other exposures as well. This might be important information for countries in which airway obstruction caused by smoking is less prevalent.
In conclusion, in the current GWAS on continuous FEV 1 /FVC levels in exclusively never-smokers, we identified HHIP and FAM13A as potential airway obstruction susceptibility genes. By strengthening our genome-side association findings by performing additional analyses on a GRS and gene expression in lung tissue (eQTL analysis), we were able to assess the effects of these common genetic variants in more detail. These 2 genes confer a risk for airway obstruction in general and have an effect regardless of the most important risk factor for COPD: cigarette smoking. Therefore these 2 genes might have an effect on the prevalence of COPD worldwide, especially in countries where COPD caused by smoking is less prevalent. This information might ultimately contribute to the understanding of cellular and molecular pathways involved in pulmonary function impairment and the development of COPD.
